The results of the first phase I/II clinical trials with recombinant human IL-15 (rhIL-15), administered either by subcutaneous (sc) or intravenous (iv) injection, and haploidentical NK cell therapy after lymphodepletion in relapsed/refractory AML patients have been recently published [133]. The gene discussed is IL15; the disease is acute myeloid leukemia.